Dennis M.  Lanfear net worth and biography

Dennis Lanfear Biography and Net Worth

Denny Lanfear is a biosimilar pioneer and biopharmaceutical leader with a proven track record of successful entrepreneurial vision and achievement. In 2010, after decades working in the biopharmaceutical industry, he founded Coherus BioSciences with the vision of improving the public’s access to high-quality, life-changing medicines. Under Mr. Lanfear’s leadership as President, CEO, and Chairman, Coherus BioSciences was transformed from an unfunded startup into the industry’s leading pure play biosimilar company, with over $1.25 billion in funding being raised since its inception. Coherus has experienced outstanding success with the launch of its first drug, UDENYCA® (pegfilgrastim-cbqv).

A dedicated entrepreneur, Mr. Lanfear founded two other companies before Coherus BioSciences: Saronyx, Inc., a drug development software services company and the biopharmaceutical company InteKrin Therapeutics. He served as CEO of both firms.

Mr. Lanfear held various senior leadership roles at Amgen Inc., serving as Vice President of Process Development before transitioning to the Commercial side of the business as Vice President of Market Development. The Process Development department was initiated and became a key strategic advantage for the company under his leadership. During his 13-year tenure at Amgen he also acquired substantial operations experience, and was tasked with integrating more than 2,500 operations and staff worldwide after the company’s explosive growth. Mr. Lanfear’s product development experience includes various leadership positions with multiple product development programs including growth factors, somatotrophins, and neurotrophins, having directed efforts from preclinical studies to Phase 3 clinical trials.

Mr. Lanfear currently serves on the board of directors of NEUVOGEN, Inc.

Mr. Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.

What is Dennis M. Lanfear's net worth?

The estimated net worth of Dennis M. Lanfear is at least $565,306.01 as of November 22nd, 2023. Mr. Lanfear owns 731,693 shares of Coherus BioSciences stock worth more than $565,306 as of November 14th. This net worth evaluation does not reflect any other investments that Mr. Lanfear may own. Additionally, Mr. Lanfear receives a salary of $1,820,000.00 as CEO at Coherus BioSciences. Learn More about Dennis M. Lanfear's net worth.

How old is Dennis M. Lanfear?

Mr. Lanfear is currently 69 years old. There are 3 older executives and no younger executives at Coherus BioSciences. Learn More on Dennis M. Lanfear's age.

What is Dennis M. Lanfear's salary?

As the CEO of Coherus BioSciences, Inc., Mr. Lanfear earns $1,820,000.00 per year. Learn More on Dennis M. Lanfear's salary.

How do I contact Dennis M. Lanfear?

The corporate mailing address for Mr. Lanfear and other Coherus BioSciences executives is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. Coherus BioSciences can also be reached via phone at (650) 649-3530 and via email at [email protected]. Learn More on Dennis M. Lanfear's contact information.

Has Dennis M. Lanfear been buying or selling shares of Coherus BioSciences?

Dennis M. Lanfear has not been actively trading shares of Coherus BioSciences during the last ninety days. Most recently, Dennis M. Lanfear sold 223,100 shares of the business's stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $2.02, for a transaction totalling $450,662.00. Following the completion of the sale, the chief executive officer now directly owns 731,693 shares of the company's stock, valued at $1,478,019.86. Learn More on Dennis M. Lanfear's trading history.

Who are Coherus BioSciences' active insiders?

Coherus BioSciences' insider roster includes James Healy (Director), Dennis Lanfear (CEO), McDavid Stilwell (CFO), and Vladimir Vexler (Insider). Learn More on Coherus BioSciences' active insiders.

Are insiders buying or selling shares of Coherus BioSciences?

In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 223,100 shares worth more than $450,662.00. The most recent insider tranaction occured on November, 22nd when CEO Dennis M Lanfear sold 223,100 shares worth more than $450,662.00. Insiders at Coherus BioSciences own 7.6% of the company. Learn More about insider trades at Coherus BioSciences.

Information on this page was last updated on 11/22/2023.

Dennis M. Lanfear Insider Trading History at Coherus BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2023Sell223,100$2.02$450,662.00731,693View SEC Filing Icon  
6/8/2021Sell31,054$13.56$421,092.24493,258View SEC Filing Icon  
11/20/2019Sell825,000$18.00$14,850,000.00125,017View SEC Filing Icon  
5/30/2019Sell32,398$19.49$631,437.02125,017View SEC Filing Icon  
5/16/2018Sell20,984$16.26$341,199.8492,619View SEC Filing Icon  
9/21/2016Sell4,060$31.75$128,905.0071,635View SEC Filing Icon  
9/16/2016Sell2,900$31.79$92,191.0071,635View SEC Filing Icon  
See Full Table

Dennis M. Lanfear Buying and Selling Activity at Coherus BioSciences

This chart shows Dennis M Lanfear's buying and selling at Coherus BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Coherus BioSciences Company Overview

Coherus BioSciences logo
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $0.77
Low: $0.77
High: $0.83

50 Day Range

MA: $0.96
Low: $0.67
High: $1.36

2 Week Range

Now: $0.77
Low: $0.66
High: $3.70

Volume

2,428,345 shs

Average Volume

2,674,254 shs

Market Capitalization

$89.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69